Filing Details
- Accession Number:
- 0001179110-14-016206
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-11-05 17:37:08
- Reporting Period:
- 2014-11-03
- Filing Date:
- 2014-11-05
- Accepted Time:
- 2014-11-05 17:37:08
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1600041 | Rutherford Paul Carter | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Evp Commercial Ops | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-11-03 | 3,000 | $40.56 | 35,244 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-11-03 | 3,000 | $112.46 | 32,244 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2014-11-04 | 4,800 | $0.00 | 37,044 | No | 4 | M | Direct | |
Common Stock | Acquisiton | 2014-11-04 | 2,736 | $109.72 | 34,308 | No | 4 | F | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | F | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2014-11-03 | 3,000 | $0.00 | 3,000 | $40.56 |
Common Stock | Restricted Stock Unit | Disposition | 2014-11-04 | 4,800 | $0.00 | 4,800 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
21,240 | 2023-02-01 | No | 4 | M | Direct | |
12,500 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
- Sale prices reported for the transactions reported here range from $112.355 to $112.52. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- The restricted stock units have a four year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 25% every year thereafter until fully vested.